ustekinumab IBD
Selected indexed studies
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (N Engl J Med, 2024) [PMID:39018531]
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (N Engl J Med, 2019) [PMID:31553833]
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. (Lancet, 2022) [PMID:35691323]
_Worker-drafted node — pending editorial review._
Connections
ustekinumab IBD is a side effect of
Sources
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (2024) pubmed
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2019) pubmed
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. (2022) pubmed
- IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction. (2024) pubmed
- Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease. (2025) pubmed
- IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials. (2025) pubmed
- Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review. (2023) pubmed
- Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. (2022) pubmed
- IBD: Ustekinumab therapy for Crohn's disease. (2017) pubmed
- Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. (2024) pubmed